[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.62, "open": 1.58, "dayLow": 1.4401, "dayHigh": 1.5988, "regularMarketPreviousClose": 1.62, "regularMarketOpen": 1.58, "regularMarketDayLow": 1.4401, "regularMarketDayHigh": 1.5988, "forwardPE": -2.2167377, "volume": 2465307, "regularMarketVolume": 2465307, "averageVolume": 1688618, "averageVolume10days": 2244240, "averageDailyVolume10Day": 2244240, "bid": 1.46, "ask": 1.56, "bidSize": 400, "askSize": 700, "marketCap": 251703008, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 760.43207, "fiftyDayAverage": 1.4356, "twoHundredDayAverage": 1.49755, "currency": "USD", "enterpriseValue": 179415728, "floatShares": 123126260, "sharesOutstanding": 167802000, "sharesShort": 10610076, "sharesShortPriorMonth": 9874736, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.063200004, "heldPercentInsiders": 0.099870004, "heldPercentInstitutions": 0.26694, "shortRatio": 5.49, "shortPercentOfFloat": 0.0828, "impliedSharesOutstanding": 181227008, "bookValue": 0.907, "priceToBook": 1.6538037, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -128603000, "trailingEps": -0.8, "forwardEps": -0.68, "enterpriseToRevenue": 542.041, "enterpriseToEbitda": -1.751, "52WeekChange": -0.12903225, "SandP52WeekChange": 0.24176979, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ATAI", "underlyingSymbol": "ATAI", "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "firstTradeDateEpochUtc": 1624023000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "8699f3bf-7398-34d0-b0ba-129948e2583d", "messageBoardId": "finmb_710359021", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.5, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 85920000, "totalCashPerShare": 0.535, "ebitda": -102440000, "totalDebt": 23807000, "quickRatio": 4.374, "currentRatio": 5.807, "totalRevenue": 331000, "debtToEquity": 16.271, "revenuePerShare": 0.002, "returnOnAssets": -0.25405002, "returnOnEquity": -0.62773, "grossProfits": 331000, "revenueGrowth": -0.54, "grossMargins": 1.0, "operatingMargins": -565.05, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]